Cyclic vomiting syndrome involves a chronic gut-brain interaction disorder that leads to recurrent crippling bouts of nausea, vomiting, and pain in the abdomen. In the modern world of research, Protheragen is pioneering rare gastrointestinal disorders and is an expert on cyclic vomiting syndrome. Our company provides a wide array of services including diagnostic and therapeutic research to accelerate preclinical drug discovery and development, all curated to be delivered from concept to completion.

Overview of Cyclic Vomiting Syndrome

Cyclic vomiting syndrome is marked by episodic and severe vomiting that occurs repeatedly and without warning, alternating with periods of relative calm. While primarily seen in children and adolescents, this disorder can continue into adulthood as well. The recognition of different cyclic vomiting syndrome subtypes is possible through a detailed history of the disease and includes catamenial cyclic vomiting syndrome, cannabinoid hyperemesis syndrome, mood disorder-associated disease, and diet-related diseases.

Fig.1 Phases that define cyclic vomiting syndrome. (Jiménez-Castillo, R. A., et al., 2024)

Pathogenesis of Cyclic Vomiting Syndrome

The precise cause remains unclear but hypothesized possible causes include genetic components (like polymorphisms), changes in the nervous system, autonomic system dysregulation, and environmental components (like the use and misuse of cannabis).

Migraines and cyclic vomiting syndrome have all been associated with some degree of mitochondrial dysfunction. Certain cyclic vomiting syndrome cases in children seem to have some genetic associations with mitochondrial dysfunction, such as polymorphisms in the mitochondrial DNA (16519T and 3010A) or other deletions within the mitochondrial DNA.

Fig.2 Potential pathophysiological mechanisms. (Hasler, W. L., et al., 2019)

Therapeutics Development for Cyclic Vomiting Syndrome

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

The multifaceted approach we take addresses an extensive range of research operations. It commences with sophisticated diagnostics research for critical biomarker identification and precise diagnostic tool development. At the same time, we have strong therapeutic research services that allow us to explore new therapy possibilities with modern molecular and cellular techniques. One of the primary goals of my work is to develop accurate human disease models that capture human pathological conditions.

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody

• Therapeutic Peptide
• Therapeutic Protein
• Microbiome Therapeutic
• More

Animal Model Development Services for Cyclic Vomiting Syndrome

Animal models aid in the comprehension of disease progression and serve as evaluation systems for new therapeutic agents. At our company, we are dedicated to advancing research in cyclic vomiting syndrome through our specialized animal model development services. We provide custom-tailored animal models for vomiting to help in your research as well as aid in drug development and therapeutic exploration.

At Protheragen, everything we do starts with innovation, quality, and collaboration. We aim to revolutionize rare gastrointestinal disease research by applying cutting-edge science and a client-first approach. Our expertise in the fields of drug therapies pharmacokinetics and safety ensures that all candidate therapies undergo extensive evaluation before human trials commence. For any questions, or to learn more about our services, feel free to get in touch with us.

References

• Hasler, William L et al. "Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions." Neurogastroenterology and motility 31 (2019): e13607.
• Jiménez-Castillo, R A et al. "Cyclic vomiting syndrome: From pathophysiology to treatment." Revista de gastroenterologia de Mexico (English) 89.3 (2024): 389-403.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.